Passa al contenuto
Merck

β3-Adrenoceptor redistribution impairs NO/cGMP/PDE2 signalling in failing cardiomyocytes.

eLife (2020-04-02)
Sophie Schobesberger, Peter T Wright, Claire Poulet, Jose L Sanchez Alonso Mardones, Catherine Mansfield, Andreas Friebe, Sian E Harding, Jean-Luc Balligand, Viacheslav O Nikolaev, Julia Gorelik
ABSTRACT

Cardiomyocyte β3-adrenoceptors (β3-ARs) coupled to soluble guanylyl cyclase (sGC)-dependent production of the second messenger 3',5'-cyclic guanosine monophosphate (cGMP) have been shown to protect from heart failure. However, the exact localization of these receptors to fine membrane structures and subcellular compartmentation of β3-AR/cGMP signals underpinning this protection in health and disease remain elusive. Here, we used a Förster Resonance Energy Transfer (FRET)-based cGMP biosensor combined with scanning ion conductance microscopy (SICM) to show that functional β3-ARs are mostly confined to the T-tubules of healthy rat cardiomyocytes. Heart failure, induced via myocardial infarction, causes a decrease of the cGMP levels generated by these receptors and a change of subcellular cGMP compartmentation. Furthermore, attenuated cGMP signals led to impaired phosphodiesterase two dependent negative cGMP-to-cAMP cross-talk. In conclusion, topographic and functional reorganization of the β3-AR/cGMP signalosome happens in heart failure and should be considered when designing new therapies acting via this receptor.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Laminina, 1-2 mg/mL in Tris-buffered saline, 0.2 μm filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Sieroalbumina, lyophilized powder, essentially fatty acid free, ≥96% (agarose gel electrophoresis)
Sigma-Aldrich
(−)-Isoproterenol hydrochloride
Sigma-Aldrich
Creatine monohydrate, ≥98%
Sigma-Aldrich
Anti-α-Actinin (Sarcomeric) antibody, Mouse monoclonal, clone EA-53, purified from hybridoma cell culture
Sigma-Aldrich
EHNA hydrochloride, ≥98% (HPLC)
Sigma-Aldrich
(±)-Carnitine hydrochloride, ≥98% (TLC)
Sigma-Aldrich
Vinpocetine, ≥98%, solid
Sigma-Aldrich
Cilostamide, phosphodiesterase inhibitor